Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds

Johanneke J Akershoek1,2, Katrien M Brouwer1,2, Marcel Vlig2

  • 1Department of Plastic, Reconstructive and Hand Surgery, Research Institute MOVE, VU University Medical Center, Amsterdam, The Netherlands.

Plos One
|June 15, 2017
PubMed

Insights

Atorvastatin improved burn wound healing and graft take in pigs by reducing inflammation, while Losartan impaired healing in full-thickness wounds. Differential effects highlight targeted therapeutic potential for burn scar prevention.

Area of Science:

  • Regenerative Medicine
  • Wound Healing Research
  • Dermatology

Background:

  • Burn wound healing often involves excessive inflammation and fibrosis, leading to scarring.
  • The Renin Angiotensin System (RAS) plays a role in fibrotic processes in various organs.
  • Statins and Angiotensin Receptor Blockers (ARBs) can modulate local RAS activity and reduce fibrosis.

Purpose of the Study:

  • To investigate the efficacy of Atorvastatin, Losartan, or their combination in improving burn wound healing.
  • To assess the impact of RAS inhibition on fibrosis and scar formation in burn wounds.
  • To evaluate differential effects on full-thickness and partial-thickness burn models.

Main Methods:

  • Yorkshire pigs received full and partial thickness burn wounds.
  • Oral administration of Atorvastatin, Losartan, or combination therapy initiated on post-burn day 1 for 28 days.
  • Full-thickness wounds underwent split-thickness skin grafting; partial-thickness wounds received conservative care.

Main Results:

  • Atorvastatin enhanced graft take and wound closure in full-thickness wounds, with reduced neutrophils and alpha-smooth muscle actin (α-SMA) positive cells.
  • Losartan and combination therapy diminished graft take, increased wound contraction, and worsened scar outcomes in full-thickness wounds.
  • Losartan reduced α-SMA+ fibroblasts and contraction in partial-thickness wounds, indicating differential effects based on wound type.

Conclusions:

  • Atorvastatin accelerates healing in full-thickness burn wounds, potentially by reducing inflammation.
  • Losartan negatively impacts graft survival in full-thickness wounds, suggesting delayed administration post-transplantation.
  • RAS inhibition demonstrates differential effects on burn wound healing, necessitating tailored therapeutic strategies.

Related Concept Videos

Burn Injuries01:22

Burn Injuries

Burn injuries occur when the skin and underlying tissues are damaged due to exposure to heat, electricity, chemicals, radiation, or friction. They can vary in severity, from minor superficial burns to severe deep burns that can be life-threatening.
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
4.8K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K